NCT05380635View on ClinicalTrials.gov

PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

May 9, 2022

Primary Completion Date

August 16, 2022

Study Completion Date

August 16, 2022

Conditions

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Interventions

DRUG

Hypericin

HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.

Trial Locations (1)

14450

Rochester Skin Lymphoma Medical Group, Fairport

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Soligenix

INDUSTRY

NCT05380635 - PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma | Biotech Hunter | Biotech Hunter